CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
更低毒性 CAR-T 细胞治疗的 PO4 潜力
英文原题：The PO4-tential for Less Toxic CAR T-cell Therapies.
查看英文原题
The PO4-tential for Less Toxic CAR T-cell Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法已在部分复发/难治性血液肿瘤患者中产生了显著且持久的缓解。然而，诸如免疫效应细胞相关神经毒性综合征（ICANS）等危及生命的毒性反应仍是广泛推广此类疗法的挑战。在本期中，Tang及其同事证明了低磷血症与CAR-T 细胞诱导的ICANS之间存在关联。需要前瞻性研究来确定磷酸盐监测是否是ICANS发生的早期预测指标，以及维持磷酸盐水平是否具有作为预防策略的作用。参见Tang等人第1433页（4）的相关文章。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has yielded remarkable and durable responses for some patients with relapsed and refractory blood cancers.
However, life-threatening toxicities such as immune effector cell-associated neurotoxicity syndrome (ICANS) remain a challenge for broad delivery of such therapies. In this issue, Tang and colleagues demonstrate an association between hypophosphatemia and CAR T cell-induced ICANS. Prospective studies are required to establish if phosphate monitoring is an early predictor for ICANS occurrence and if maintenance of phosphate levels has a role as a preventative strategy. See related article by Tang et al. , p. 1433 (4).
论文信息
- 作者
- Tobin JWD、Green MR、Gandhi MK
- 单位
- Mater Research University of Queensland, Brisbane, Queensland, Australia.Australia
- 文献类型
- 评论
- 期刊
- Cancer immunology research2022 Dec 2
- 原文标识
- PubMed 36327248 · DOI 10.1158/2326-6066.CIR-22-0793